Supplemental Figures Legends
, related to Figure 1. Role of HuR in differentiation and its control by miR-133 A. C 2 C 12 cells differentiated for 48 hours and treated either with control (si Scr) or anti HuR (si HuR) siRNAs. Images were taken with a Zeiss Axio Observer A1 microscope at 10X magnification. B. Left panels: luciferase activity of short and long Luc-HuRwt and mutant derivatives cotransfected in HeLa cells together with a control plasmid (Mock) or with a plasmid expressing miR-133 (p-133) . FLuc/RLuc RQ is shown with respect to a control sample set to a value of 1. Right panels: Graphs showing the levels of miR-133 in the samples treated as in left panels, measured by qRT-PCR. Data were derived from at least three independent experiments; error bars represents standard error. C. Levels of pMD1 and pMD1Δ133 in samples treated as in Fig. 1C , measured by RT-PCR. GAPDH is used as control. Same cellular equivalents of nuclear (Nuc) and cytoplasmic (Cyt) protein extracts from C 2 C 12 cells, differentiated for the indicated time points, were analysed by Western blot analysis using antiHuR antibody. Hprt is used as loading control as well as a control for contamination between the nuclear and cytoplasmic fractions. B. Schematic representation indicating the species deriving from the linc-MD1 locus and the oligo used for their detection by RT-PCR. C. qRT-PCR analysis on RNA from HeLa cells trasfected with p133a, p133b or empty vector (negative control). cDNA was prepared using Exiqon miRCURY cDNA synthesis kit and analyzed with LNA probes targeting miR-133a or miR-133b (black and white bars respectively). qRT-PCR was performed on pure cDNAs and mixed ones made of 25% of miR-133a, 50% of both or 25% miR-133b. D. Graph showing the 133b/133a reads ratio measured by small RNA-seq on RNA samples obtained from differentiating C2C12 cells treated with control (si-Scr) and anti HuR (si-HuR) siRNAs. A general decrease of reads was obtained in the absence of HuR, probably reflecting the effect of HuR on transcriptional factors such as MyoD, Myog, p21. Nevertheless, in these conditions, the decrease of miR-133b results lower than that of its paralogue miR-133a. MiRNA reads are available as a separate spreadsheet named "smallrnaseq". E. RT-PCR showing the level of linc-MD1 in differentiating C2C12 cells upon 10ng/ml leptomycin B (LMB) treatment . GAPDH is used as control. F. miR-133b levels measured by qRT-PCR performed on cDNA prepared with Qiagen miScript system using RNA form HeLa cells treated with an empty vector (p-, white bars) and an HuR overexpressing vector (pHuR, black bars) in combination either with a linc-MD1 expressing vector (pMD1wt) or its mutant derivative lacking the HuR binding site (pMD1ΔHuR). miR-133b levels normalized to U6snRNA are set to 1 in the p-samples. Error bars represent standard error from 3 independent experiments. G. Western blot analysis showing the level of the HuR protein in the nuclear fractions from Hela cells upon HuR depletion. Actinin is used as loading control. H. in vitro processing with 32 P-UTP labelled pri-miR-133b and pri-miR-9-2, with nuclear extracts from Hela cells treated with control (si Scr) and anti HUR (si HuR) siRNAs. Samples with no extract (mock) were used as control. The pre-miR-133b and pre-miR-9-2 are indicated as well as a panel with a magnification of higher exposition for pre-miR-133b visualization. The asterisk indicates a pri-miR-9-2 unspecific cleavage. The experiment has been performed two times. I. Putative structure of the pri-miR-133b stem-loop. The mature miR-133b sequence is shown in bold. Arrows indicate the positions of the Drosha cleavage sites. In the summary page a description of the RNAseq data is available. Length, number and sequence of reads are reported together with miRNA name for each of the four lanes (A1-4) . A 1,2 lanes correspond to scramble siRNA-treated cells, A 3,4 to HuR siRNA-treated cells. miR-133 a and b reads are reported separately.
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Extended experimental procedures
microRNA binding predictions miR-133 and miR-135 target predictions were performed using the miRanda algorithm, setting all the parameters to the default values. Results were then filtered for expression in muscle tissue according to the Gene Expression Barcode dataset: consensus proportion was set to 95% of the samples for the tissue named Skeletal Muscle: Normal in the Mouse_4302 platform. The best 20 filtered targets of miR-133 and miR-135, ranked for the miRanda score, were reported in Table S1 .
Luciferase constructs and assays: 3'UTR of HuR was amplified from mouse genomic DNA by polymerase chain reaction (PCR) with the oligos listed in Plasmid construction: The pMD1, p133 and p135 plasmids used in this work correspond to pMD1-ΔDrosha, pmiR-133a/b and pmiR-135a/b (pooled) described in Cesana et al. (2011) respectively. The pMD1ΔHuR plasmid, carrying the mutation in the HuR putative binding site, was generated by reverse PCR on pMD1-ΔDrosha using the oligonucleotides described in Table S2 . pHuR was produced by cloning HuR cDNA into a pcDNA 3.1 (+) vector (Invitrogen).
Drosha in vitro processing:
In vitro processing assay was carried out as previously described (Lee and Kim, 2007 ) . Pri-miRNA substrates were prepared by in vitro transcription, using T7 RNA polymerase (Promega), from PCR amplified templates (oligonucleotides are listed in Table S2 ), in the presence of [α-32P]UTP (Perkin-elmer). 40'000 cpm of each pri-miRNA transcript were incubated with 15 µg of C 2 C 12 nuclear extract cells at 37°C for 90 minutes.
Small RNA sequencing: miRNA libraries were constructed and sequenced by the Illumina Cluster Station and HiSeq-2000 (Illumina Inc, CA, USA) at Beijing Genomics Institute at Shenzhen according to the manufacturer's protocol. Reads were aligned to mouse miRNA sequences present in miRBase (GRCm38). miRNA reads are available as a separate spreadsheet named "smallRNAseq".
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